Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17274510 | 0.88 | GRIK1 (0.32) | GRIK1GRIK2 | |
| SCHEMBL28427874 | 0.88 | GRIK1 (0.32) | GRIK1GRIK2 | |
| SCHEMBL7027181 | 0.85 | GRIK1 (0.33) | GRIK1GRIK2 | |
| SCHEMBL7024176 | 0.85 | GRIK1 (0.33) | GRIK1GRIK2 | |
| SCHEMBL28427879 | 0.82 | GRIK1 (0.36) | GRIK1GRIK2 | |
| SCHEMBL28456126 | 0.80 | — | — | |
| SCHEMBL28436247 | 0.76 | HTR2A (0.45) | GRIK1GRIK2 | |
| SCHEMBL28436250 | 0.74 | GRIK1 (0.32) | GRIK1GRIK2 | |
| SCHEMBL428739 | 0.73 | — | — | |
| SCHEMBL7024183 | 0.72 | GRIK1 (0.33) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115872962-B | Beraprost sodium intermediate and preparation method thereof | 成都硕德药业有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-115872962-B | Beraprost sodium intermediate and preparation method thereof | 成都硕德药业有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-107802623-B | Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders | 开曼化学股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-106748951-B | Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions | 开曼化学股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-10640481-B2 | Methods for producing Beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190202797-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2019-07-04 | — | — | US | disclosed |
| US-10246430-B2 | Methods for producing Beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180265490-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2018-09-20 | — | — | US | disclosed |
| US-10005753-B2 | Methods for producing beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170166545-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265490-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | UMPS, GGPS1, DHPS | GRIK1 3022/4885GRIK2 3055/4885 |
| US-20170166545-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | CYP51A1, COASY, BLVRB | GRIK1 2608/4885GRIK2 2680/4885 |
| US-10246430-B2 | Methods for producing Beraprost and its derivatives | UMPS, GGPS1, DHPS | GRIK1 3022/4885GRIK2 3055/4885 |
| US-10005753-B2 | Methods for producing beraprost and its derivatives | CYP51A1, COASY, BLVRB | GRIK1 2608/4885GRIK2 2680/4885 |
| US-10640481-B2 | Methods for producing Beraprost and its derivatives | UMPS, GGPS1, DHPS | GRIK1 3022/4885GRIK2 3055/4885 |
| US-20190202797-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | UMPS, GGPS1, DHPS | GRIK1 3022/4885GRIK2 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.